Bayer Takes On 2 More Generics Makers Over Yasmin

Law360, New York (April 21, 2008, 12:00 AM EDT) -- German pharmaceutical company Bayer AG has sued Watson Pharmaceuticals Inc. and Novartis AG unit Sandoz Inc., seeking to prevent them from marketing a generic version of the oral contraceptive Yasmin.

In a complaint filed Friday with the U.S. District Court for the Southern District of New York, Bayer alleges that Watson and Sandoz infringed one of its patents by filing abbreviated new drug applications for drospirenone and ethinyl estradiol tablets.

Drospirenone and ethinyl estradiol are the active ingredients in Yasmin.

Watson, a Corona, Calif.-based specialty pharmaceutical...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.